SARASOTA, Fla. and MADRID, Dec. 16,
2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:
INVO), a medical device company focused on commercializing the
world's only in vivo culture system (IVC), INVOcell®, today
announced the Company has entered into an expanded agreement with
Ovoclinic, a group of clinics specialized in assisted reproductive
treatments with four locations across Spain (Madrid, Marbella, Málaga, Ceuta) and
collaborating centers around Europe, to accelerate adoption of INVOcell
within their markets. The agreement includes the expanded adoption
of INVOcell within Ovoclinic locations as well as establishing an
INVO Center of Excellence for future training for the European
Market.
INVO began commercialization in Spain through direct sales efforts in early
2021, primiarily to support Ovoclinic's desire to begin working
with the INVOcell technology. Ovoclinic was trained and began
offering the INVOcell solution to select patients during the year,
and has reported successful results with patients primarily between
30 and 50 years of age. Ovoclinic will now begin offering INVOcell
and the IVC Procedure to all its patients and become an INVO Center
of Excellence with its Marbella location serving as the training
facility. Ovoclinic will use content provided by INVO, which
includes utilizing "An INVO Center" for its marketing and patient
education materials to promote INVOcell and the IVC
Procedure. As a pioneer in egg cryopreservation and the
creators of the first egg bank in Europe with its Ovobank operation, Ovoclinic
intends to help promote INVOcell to its Ovobank clinical partners
across the European Union.
"Since our initial relationship began earlier this year, the
teams at INVO and Ovoclinic have worked closely together to train
their medical team and introduce the INVOcell solution to patients
in need of advanced fertility treatment," commented Stece Shum, CEO
of INVO Bioscience. "We are thrilled to be expanding our
relationship with Ovoclinic through this agreement, which reflects
their enthusiasm and belief in the INVOcell treatment option and
desire to not only expand the technology in their own clinics, but
also utilize their strong reputation and current operations in
Spain to become a center of
excellence to help promote INVOcell to other fertility clinics in
the EU. We look forward to working closely with Ovoclinic to
help expand adoption and achieve our goal of advancing assisted
reproductive treatment throughout Spain to the many individuals that need
care."
Spain has a total population of
approximately 47 million people. According to the World Bank,
Spain has one of the lowest
fertility rates in Europe,
affecting approximately 15% of the population, or one in seven
couples of reproductive ages. According to reports, in 2010, there
were approximately one million couples requesting assisted
reproductive treatment, however only 22% received one or more
assisted reproductive treatment cycles. The average waiting time
for an IUI or IVF cycle in a public health facility was 339
days.
"After several successful trials implementing the exciting
INVOcell fertility treatment, Ovoclinic aims to provide its
patients with this effective alternative to the processes used so
far in Spain in the field of
reproductive medicine," says Cristina
Gonzalez, embryologist and Quality Manager of Ovoclinic
laboratories. "We consider INVOcell to be an effective method of
natural reproduction that involves the future mother at the very
first moment of the process. We are confident that this innovative
treatment will help many patients to choose this new alternative
solution to achieve their dream of forming a family by actively
participating in the reproductive process."
About Ovoclinic
Ovoclinic is a group of clinics of assisted
reproduction with presence in Marbella, Malaga, Madrid and Ceuta. We are a team of
multilingual professionals with more than 20 years of
experience in the field of assisted reproduction, both national and
international. We carry out our work with passion and dedication,
to make your dream of starting a family come true.
We are specialists in all types of assisted reproduction
treatments and complex cases. We work in partnership with
Ovobank, the first European Donor Egg Bank in Europe.
We have the best technical and human resources to deal with all
kinds of infertility problems. From the simplest and most natural
treatments to the most complex and advanced techniques pioneered in
Spain, in order to achieve the
expected pregnancy.
About INVOcell
The INVOcell procedure is the first in-vivo culture (IVC) system
in the world used for the incubation of eggs and sperm during
fertilization and early embryo development within the body, as an
alternative to conventional In Vitro Fertilization (IVF) and
Intrauterine Insemination (IUI). Through its in vivo approach,
INVOcell offers patients a more natural and intimate experience
with comparable results at a lower cost.
About INVO Bioscience
We are a medical device company focused on creating simplified,
affordable treatments for patients diagnosed with infertility. Our
solution, the INVO® Procedure, is a revolutionary in vivo method of
vaginal incubation that offers patients a more natural and intimate
experience. Our lead product, the INVOcell®, is a patented medical
device used in infertility treatment and is considered an Assisted
Reproductive Technology (ART). The INVOcell® is the first
Intravaginal Culture (IVC) system in the world used for the natural
in vivo incubation of eggs and sperm during fertilization and early
embryo development, as an alternative to traditional In Vitro
Fertilization (IVF) and Intrauterine Insemination (IUI). Our
mission is to increase access to care and expand fertility
treatment across the globe with a goal to lower the cost of care
and increase the availability of care. For more information, please
visit https://www.invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at https://www.sec.gov/. We are under no
obligation to (and expressly disclaim any such obligation to)
update or alter our forward-looking statements, whether as a result
of new information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-enters-into-agreement-with-ovoclinic-in-spain-to-expand-invocell-commercialization-301446002.html
SOURCE INVO Bioscience, Inc.